Epigenomics AG (STU:ECX) Additional Paid-In Capital : €102.19 Mil(As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG Additional Paid-In Capital?

Epigenomics AG's quarterly additional paid-in capital declined from Dec. 2022 (€102.36 Mil) to Mar. 2023 (€102.19 Mil) but then increased from Mar. 2023 (€102.19 Mil) to Jun. 2023 (€102.19 Mil).

Epigenomics AG's annual additional paid-in capital increased from Dec. 2020 (€87.42 Mil) to Dec. 2021 (€99.76 Mil) and increased from Dec. 2021 (€99.76 Mil) to Dec. 2022 (€102.36 Mil).

Epigenomics AG Additional Paid-In Capital Historical Data

The historical data trend for Epigenomics AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Additional Paid-In Capital Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

68.80

69.25

87.42

99.76

102.36

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															98.87	98.88	102.36	102.19	102.19

Epigenomics AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Epigenomics AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (STU:ECX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EPGNF:USA

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.